Moderna and Merck said Wednesday that an experimental personalized mRNA cancer vaccine met its primary endpoint in a late-stage clinical trial.
The results suggest a significant breakthrough in treating melanoma, the deadliest form of skin cancer, by extending disease-free survival for high-risk patients.
The trial involved more than 1,100 patients [1]. Participants received the personalized mRNA vaccine in combination with Keytruda, an immunotherapy drug developed by Merck. The combination therapy significantly reduced the risk of cancer recurrence and metastasis compared to using Keytruda alone.
Personalized mRNA vaccines are designed to target specific mutations found in an individual's tumor. By teaching the immune system to recognize these unique markers, the treatment aims to prevent the cancer from returning after initial surgery.
Market reaction to the announcement was immediate. Moderna's stock price saw a sharp increase, with reports indicating the value rose by about 90% [2] or more than doubled [3].
The companies said the vaccine is intended for patients at high risk of recurrence. The late-stage trial focused on whether the additive effect of the mRNA vaccine could improve long-term outcomes beyond the current standard of care.
“The combination therapy significantly reduced the risk of cancer recurrence and metastasis.”
This development marks a shift toward personalized oncology, where treatments are tailored to the genetic profile of a patient's specific tumor. If approved, the combination of mRNA technology and existing immunotherapies could establish a new standard of care for melanoma, potentially transforming a high-recurrence disease into a manageable condition through targeted prevention.
